

Press release February 18, 2020

**Dr Kristian Sandberg suggested as new board member**

The board of directors of Lipum AB has suggested Dr Kristian Sandberg to be elected as new member of the board at an extraordinary general meeting held in Umeå on March 3, 2020.

Lipum has identified bile salt-stimulated lipase (BSSL) as a novel target for treatment of chronic inflammatory diseases. The lead candidate drug SOL-116 is a fully humanized monoclonal antibody that now is in the stage of production development. Toxicological studies are in the plans and clinical trials will be initiated during 2021.

*Dr Kristian Sandberg is an experienced leader in the pharmaceutical industry's research and development. He has over 20 years’ experience from AstraZeneca in various functions within R&D, primarily with project leader responsibilities. Kristian was previously, in his role as director at Scilifelab, leading the development and optimization of Lipum’s candidate drug. We are indeed very pleased that Kristian now joins the board, says chairman of the board Ulf Björklund.*

**Contact details**Einar Pontén, CEO

E-mail: einar.ponten@lipum.se

Mobile: +46 70 5783495

Web: www.lipum.se

**About Lipum AB**Lipum is a biopharmaceutical company focused on chronic inflammatory diseases. The company has its roots in academic research at Umeå University and is located in the Umeå Biotech Incubator in Umeå, Sweden. Lipum has support from European Commission and the program Horizon 2020.